BET家族及其抑制剂在肿瘤中的研究进展

摘要
图/表
参考文献(27)
相关文章 (15)

全文: PDF (617 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要溴结构域和超末端结构域（BET）家族属于溴结构域蛋白家族，在多种肿瘤中BET家族表达上调，其与细胞生长、增殖分化、凋亡坏死等多种生物学过程相关，进而参与调控肿瘤发生发展的过程。BET家族多种抑制剂的Ⅰ期或Ⅱ期临床实验正在进行中，相关研究结果表明，BET抑制剂单药或联合现有药物在治疗多种肿瘤中均有明确的效果，因此，其有望成为肿瘤治疗的新靶点。本文通过复习相关文献对近年来BET家族及其抑制剂在肿瘤研究中的进展进行综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周晓程志祥

关键词 ：溴结构域和超末端结构域, 抑制剂, 肿瘤, 临床试验

Abstract：Bromodomain and extra terminal domain (BET) family is one of bromodomain proteins, which is up-regulated in various tumors and involved in tumor pathogenesis by regulating cell growth, proliferation and differentiation, apoptosis and necrosis. Several BET inhibitors have been developed and clinically tested, the antitumor efficacy of BET inhibitor alone or in combination with existing drugs has been identified in different tumors types, so it may become a new target for tumor treatment. This paper summarizes the current knowledge of BETs and its inhibitors in tumor.

Key words： Bromodomain and extra terminal domain Inhibitor Tumor Clinical trail

基金资助:国家自然科学基金资助项目（81372395）。

通讯作者: 程志祥（1972.7-），男，博士，留美博士后，副主任医师，副教授，硕士研究生导师；研究方向：抗肿瘤药物耐药机制。

作者简介: 周晓（1992.2-），女，南京医科大学第二临床医学院2016级肿瘤学专业在读专业型硕士研究生；研究方向：BET抑制剂抗肿瘤机制。

引用本文:

周晓程志祥. BET家族及其抑制剂在肿瘤中的研究进展[J]. 中国医药导报, 2019, 16(8): 26-29,46.
ZHOU Xiao CHENG Zhixiang. Advance of BET family and its inhibitors in tumor. 中国医药导报, 2019, 16(8): 26-29,46.

链接本文:

http://www.yiyaodaobao.com.cn/CN/ 或 http://www.yiyaodaobao.com.cn/CN/Y2019/V16/I8/26

[1] Ferri E，Petosa C，McKenna CE. Bromodomains：Structure，function and pharmacology of inhibition [J]. Biochem Pharmacol，2016，106：1-18.
[2] Cheung KL，Zhang F，Jaganathan A，et al. Distinct Roles of Brd2 and Brd4 in Potentiating the Transcriptional Program for Th17 Cell Differentiation [J]. Mol Cell，2017，65（6）：1068-1080.e5.
[3] Jung M，Gelato KA，Fernández-Montalván A，et al. Targeting BET bromodomains for cancer treatment [J]. Epigenomics，2015，7（3）：487-501.
[4] Huang Y，Nahar S，Nakagawa A，et al. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment [J]. Clin Cancer Res，2016，22（16）：4259-4270.
[5] Sakurai N，Inamochi Y，Inoue T，et al. BRD4 regulates adiponectin gene induction by recruiting the P-TEFb complex to the transcribed region of the gene [J]. Sci Rep，2017，7（1）：11962.
[6] Konuma T，Yu D，Zhao C，et al. Structural Mechanism of the Oxygenase JMJD6 Recognition by the Extraterminal（ET）Domain of BRD4 [J]. Sci Rep，2017，7（1）：16272.
[7] Bourova-Flin E，Chuffart F，Rousseaux S，et al. The Role of Bromodomain Testis-Specific Factor，BRDT，in Cancer：A Biomarker and A Possible Therapeutic Target [J]. Cell J，2017，19（Suppl 1）：1-8.
[8] Stathis A，Bertoni F. BET Proteins as Targets for Anticancer Treatment [J]. Cancer Discov，2018，8（1）：24-36.
[9] Xu Y，Vakoc CR. Targeting Cancer Cells with BET Bromodomain Inhibitors [J]. Cold Spring Harb Perspect Med，2017，7（7）. Pii：a026674.
[10] Wang R，You J. Mechanistic analysis of the role of bromodomain-containing protein 4（BRD4）in BRD4-NUT oncoprotein-induced transcriptional activation [J]. J Biol Chem，2015，290（5）：2744-2758.
[11] Zee BM，Dibona AB，Alekseyenko AA，et al. The Oncoprotein BRD4-NUT Generates Aberrant Histone Modification Patterns [J]. PLoS One，2016，11（10）：e0163820.
[12] Saygin C，Carraway HE. Emerging therapies for acute myeloid leukemia [J]. J Hematol Oncol，2017，10（1）：93.
[13] Saenz DT，Fiskus W，Manshouri T，et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells [J]. Leukemia，2017，31（3）：678-687.
[14] Tontsch-Grunt U，Rudolph D，Waizenegger I，et al. Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo [J]. Cancer Lett，2018，421：112-120.
[15] Bui MH，Lin X，Albert DH，et al. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies [J]. Cancer Res，2017，77（11）：2976-2989.
[16] Marcotte R，Sayad A，Brown KR，et al. Functional Genomic Landscape of Human Breast Cancer Drivers，Vulnerabilities，and Resistance [J]. Cell，2016，164（1/2）：293-309.
[17] Feng Q，Zhang Z，Shea MJ，et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer [J]. Cell Res，2014，24（7）：809-819.
[18] Andrieu GP，Denis GV. BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition [J]. Mol Cancer Res，2018，16（4）：580-586.
[19] Lenhart R，Kirov S，Desilva H，et al. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression [J]. Mol Cancer Ther，2015，14（10）：2167-2174.
[20] Liao YF，Wu YB，Long X，et al. High level of BRD4 promotes non-small cell lung cancer progression [J]. Oncotarget，2016，7（8）：9491-9500.
[21] Lam LT，Lin X，Faivre EJ，et al. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors [J]. Mol Cancer Ther，2017，16（8）：1511-1520.
[22] Zhang D，Leal AS，Carapellucci S，et al. Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762 [J]. Cancer Prev Res（Phila），2018，11（3）：143-156.
[23] Wang J，Wang Y，Mei H，et al. The BET bromodomain inhibitor JQ1 radiosensitizes non-small cell lung cancer cells by upregulating p21 [J]. Cancer Lett，2017，391：141-151.
[24] Wyce A，Matteo JJ，Foley SW，et al. MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers [J]. Oncogenesis，2018，7（4）：35.
[25] Jin X，Yan Y，Wang D，et al. DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4 [J]. Mol Cell，2018，71（4）：592-605.e4.
[26] Berthon C，Raffoux E，Thomas X，et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia：a dose-escalation，phase 1 study [J]. Lancet Haematol，2016，3（4）：e186-195.
[27] Lewin J，Soria JC，Stathis A，et al. Phase Ib Trial With Birabresib，a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins，in Patients With Selected Advanced Solid Tumors [J]. J Clin Oncol，2018：JCO2018 782292.